Essure®植入物切除术后有症状患者的临床和组织病理学相关性:一项横断面研究。

IF 1.9 4区 医学 Q3 OBSTETRICS & GYNECOLOGY European Journal of Contraception and Reproductive Health Care Pub Date : 2023-08-01 Epub Date: 2023-06-27 DOI:10.1080/13625187.2023.2218953
Alexis Trecourt, Mojgan Devouassoux-Shisheboran, Erdogan Nohuz, Emanuele Cerruto, Stephanie Moret, Doriane Hallez, Chloe Miguet-Bensouda, Gautier Chene
{"title":"Essure®植入物切除术后有症状患者的临床和组织病理学相关性:一项横断面研究。","authors":"Alexis Trecourt,&nbsp;Mojgan Devouassoux-Shisheboran,&nbsp;Erdogan Nohuz,&nbsp;Emanuele Cerruto,&nbsp;Stephanie Moret,&nbsp;Doriane Hallez,&nbsp;Chloe Miguet-Bensouda,&nbsp;Gautier Chene","doi":"10.1080/13625187.2023.2218953","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Many concerns have been raised about adverse effects related to Essure<sup>®</sup> device. Several pathophysiological hypotheses have been proposed including allergic reactions, Autoimmune/Autoinflammatory Syndrome Induced by Adjuvants, galvanic corrosion with release of heavy metals and inflammation. In the present study, we aimed to focus on inflammation process by performing a histopathological evaluation of Fallopian tubes in symptomatic patients with Essure<sup>®</sup> removal.</p><p><strong>Materials and methods: </strong>A cross-sectional study with identification of the type of inflammatory response and characterisation of inflammatory cells in the surrounding tubal tissue around the Essure<sup>®</sup> (STTE) and at distance from the implant. Histopathological and clinical correlations were also investigated.</p><p><strong>Results: </strong>In the STTE from 47 cases, acute inflammation was observed in 3/47 (6.4%) cases. Chronic inflammation with lymphocytes (42.5%, 20/47) was associated with a significant higher pre-operative pain score (<i>p</i> = .03). Fibrosis was noted in 43/47 (91.5%) cases. Fibrosis without lymphocytes (51.1%, 24/47) was statistically associated with significant reduced pain (<i>p</i> = .04). At distance from the Essure<sup>®</sup> implant, only chronic inflammation with lymphocytes was present in 10/47 (21.7%) cases.</p><p><strong>Conclusions: </strong>Inflammation response do not seem to be enough to explain all the Essure-related adverse outcomes, suggesting the involvement of other biological mechanisms.</p><p><strong>Clinicaltrials.gov identifier: </strong>NCT03281564.</p>","PeriodicalId":50491,"journal":{"name":"European Journal of Contraception and Reproductive Health Care","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Clinical and histopathological correlations in symptomatic patients with salpingectomy for Essure<sup>®</sup> implant removal: a cross-sectional study.\",\"authors\":\"Alexis Trecourt,&nbsp;Mojgan Devouassoux-Shisheboran,&nbsp;Erdogan Nohuz,&nbsp;Emanuele Cerruto,&nbsp;Stephanie Moret,&nbsp;Doriane Hallez,&nbsp;Chloe Miguet-Bensouda,&nbsp;Gautier Chene\",\"doi\":\"10.1080/13625187.2023.2218953\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Many concerns have been raised about adverse effects related to Essure<sup>®</sup> device. Several pathophysiological hypotheses have been proposed including allergic reactions, Autoimmune/Autoinflammatory Syndrome Induced by Adjuvants, galvanic corrosion with release of heavy metals and inflammation. In the present study, we aimed to focus on inflammation process by performing a histopathological evaluation of Fallopian tubes in symptomatic patients with Essure<sup>®</sup> removal.</p><p><strong>Materials and methods: </strong>A cross-sectional study with identification of the type of inflammatory response and characterisation of inflammatory cells in the surrounding tubal tissue around the Essure<sup>®</sup> (STTE) and at distance from the implant. Histopathological and clinical correlations were also investigated.</p><p><strong>Results: </strong>In the STTE from 47 cases, acute inflammation was observed in 3/47 (6.4%) cases. Chronic inflammation with lymphocytes (42.5%, 20/47) was associated with a significant higher pre-operative pain score (<i>p</i> = .03). Fibrosis was noted in 43/47 (91.5%) cases. Fibrosis without lymphocytes (51.1%, 24/47) was statistically associated with significant reduced pain (<i>p</i> = .04). At distance from the Essure<sup>®</sup> implant, only chronic inflammation with lymphocytes was present in 10/47 (21.7%) cases.</p><p><strong>Conclusions: </strong>Inflammation response do not seem to be enough to explain all the Essure-related adverse outcomes, suggesting the involvement of other biological mechanisms.</p><p><strong>Clinicaltrials.gov identifier: </strong>NCT03281564.</p>\",\"PeriodicalId\":50491,\"journal\":{\"name\":\"European Journal of Contraception and Reproductive Health Care\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2023-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Contraception and Reproductive Health Care\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/13625187.2023.2218953\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/6/27 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Contraception and Reproductive Health Care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13625187.2023.2218953","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/6/27 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 1

摘要

目的:人们对Essure®器械的不良反应提出了许多担忧。已经提出了几种病理生理学假说,包括过敏反应、佐剂诱导的自身免疫/自身炎症综合征、重金属释放的电偶腐蚀和炎症。在本研究中,我们旨在通过对有症状的Essure®切除患者的输卵管进行组织病理学评估来关注炎症过程。材料和方法:一项横断面研究,鉴定Essure®(STTE)周围和距离植入物较远的输卵管组织中的炎症反应类型和炎症细胞特征。还研究了组织病理学和临床相关性。结果:47例STTE患者中,急性炎症发生率为6.4%(3/47)。淋巴细胞慢性炎症(42.5%,20/47)与术前疼痛评分显著升高有关(p = .03)。纤维变性43例(91.5%)。无淋巴细胞的纤维化(51.1%,24/47)在统计学上与疼痛显著减轻相关(p = .04)。在距离Essure®植入物较远的地方,10/47(21.7%)的病例中仅出现淋巴细胞慢性炎症。结论:炎症反应似乎不足以解释所有Essure相关的不良结果,这表明涉及其他生物学机制。Clinicaltrials.gov标识符:NCT03281564。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Clinical and histopathological correlations in symptomatic patients with salpingectomy for Essure® implant removal: a cross-sectional study.

Purpose: Many concerns have been raised about adverse effects related to Essure® device. Several pathophysiological hypotheses have been proposed including allergic reactions, Autoimmune/Autoinflammatory Syndrome Induced by Adjuvants, galvanic corrosion with release of heavy metals and inflammation. In the present study, we aimed to focus on inflammation process by performing a histopathological evaluation of Fallopian tubes in symptomatic patients with Essure® removal.

Materials and methods: A cross-sectional study with identification of the type of inflammatory response and characterisation of inflammatory cells in the surrounding tubal tissue around the Essure® (STTE) and at distance from the implant. Histopathological and clinical correlations were also investigated.

Results: In the STTE from 47 cases, acute inflammation was observed in 3/47 (6.4%) cases. Chronic inflammation with lymphocytes (42.5%, 20/47) was associated with a significant higher pre-operative pain score (p = .03). Fibrosis was noted in 43/47 (91.5%) cases. Fibrosis without lymphocytes (51.1%, 24/47) was statistically associated with significant reduced pain (p = .04). At distance from the Essure® implant, only chronic inflammation with lymphocytes was present in 10/47 (21.7%) cases.

Conclusions: Inflammation response do not seem to be enough to explain all the Essure-related adverse outcomes, suggesting the involvement of other biological mechanisms.

Clinicaltrials.gov identifier: NCT03281564.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.70
自引率
11.80%
发文量
63
审稿时长
>12 weeks
期刊介绍: The Official Journal of the European Society of Contraception and Reproductive Health, The European Journal of Contraception and Reproductive Health Care publishes original peer-reviewed research papers as well as review papers and other appropriate educational material.
期刊最新文献
A randomised double-blind trial to determine the bleeding profile of the prolonged-release contraceptive dienogest 2 mg/ethinylestradiol 0.02 mg versus an immediate-release formulation of drospirenone 3 mg/ethinylestradiol 0.02 mg. Medical termination of pregnancy: people's expectations and experiences in the Netherlands. Neighbourhood environment and early menarche among adolescent girls of five countries. Postpartum contraception provision across Europe: preliminary findings from a multi country survey. Response to Daungsupawong and Wiwanitkit's Letter to the Editor.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1